Innovate UK

Mulder specializes in blockchain-based traceability solutions for the medical device industry. It develops a network platform that offers real-time visibility and traceability across the entire supply chain, from raw material sourcing to patient application. This enables healthcare providers and manufacturers to verify device provenance, ensure compliance, and enhance patient safety.

Axial3D specializes in 3D printing technology tailored for healthcare. It converts patient CT and MRI scan data into precise, personalized 3D models to enhance medical professionals' understanding of abnormalities, encourage innovative surgical techniques, and improve patient outcomes.

LaennecAI is a clinical AI company specializing in chronic disease management solutions. It has developed a medical device, a digital stethoscope, which transforms modern smartphones into powerful diagnostic tools. The company's technology enables precise monitoring and analysis of respiratory and cardiac sounds, facilitating telemedicine, remote patient monitoring, and virtual wards. This ensures patients receive in-depth, reliable analysis and continuous care.

Mulder specializes in blockchain-based traceability solutions for the medical device industry. It develops a network platform that offers real-time visibility and traceability across the entire supply chain, from raw material sourcing to patient application. This enables healthcare providers and manufacturers to verify device provenance, ensure compliance, and enhance patient safety.

Kaydiar is a medical device company focused on developing innovative offloading technologies for pressure injuries. Their product range includes orthotic devices, bed mattresses, wheelchair cushions, and prosthetic sleeves, all designed to reduce pressure on damaged skin or tissue, promoting cost-effective wound care.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Siloton is a medical device company specializing in ophthalmology. It designs and develops diagnostic imaging devices, notably a portable optical coherence tomography system, coupled with cloud-based digital health tools to enhance patient care and prevent avoidable blindness.

Naitive is a population health company that develops AI-enabled clinical pathways. It uses artificial intelligence, clinical data, digital interventions, and scalable computational capabilities to enhance chronic disease case-finding, treatment, and care coordination, aiming to transform patient care and reduce associated costs.

Nami Surgical specializes in developing and providing advanced robotic surgery technology. Their core offering is ultrasonic surgical tools designed to enhance the current robotic-assisted surgery market. By simplifying and making procedures safer, they expand the use of robots in surgeries requiring ultrasonic devices, thereby improving clinical outcomes and patient care. Their solutions provide surgeons with intuitive, high-performance, and maneuverable instruments for complex surgical tasks.

Medicsen is a start-up focused on healthcare innovation, primarily through the development of advanced technology solutions. A notable project is GlycSen, a needle-free drug delivery device aimed at providing a painless treatment option for individuals with insulin-dependent diabetes. This device integrates data from continuous glucose meters and user-inputted information, utilizing a learning algorithm to facilitate real-time monitoring. It features a chatbot interface that allows patients to easily track their condition, enhancing their ability to manage diabetes effectively. Through these innovations, Medicsen aims to improve the quality of life for those living with chronic diseases.

SleepCogni is developing a sleep aid technology that delivers a wind-down process to promote sleep. The device provides cognitive-behavioral therapy through biofeedback delivered via visual, auditory, and tactile cues and is triggered manually. It monitors physiological and behavioral sleep-related measures, including heart rate, mental alertness, skin temperature, and movement using sensors on the index finger, to guide users toward sleep initiation and improve sleep quality, addressing insomnia.

machineMD is a Swiss-based medical device company focused on innovating at the intersection of neuroscience and ophthalmology. It aims to significantly enhance the measurement of brain function, with the ultimate goal of enabling accurate, swift, and early diagnosis of brain disorders in primary and secondary care settings.

GaitQ Limited is a medical device company founded in 2019 and based in Oxfordshire, United Kingdom. It specializes in developing the GaitThaw device, which addresses the issue of gait freezing in individuals with Parkinson's disease. This small and portable device employs clinically proven sensory cues to assist patients in re-establishing the connection between the brain and body, thereby facilitating smoother walking. GaitQ aims to improve mobility and enhance the quality of life for those affected by this debilitating symptom of Parkinson's disease.

Graphene Trace is a healthcare technology company that specializes in preventing pressure ulcers, a common issue among wheelchair users and hospital patients. The company's core product is a smart, pressure-sensing fabric that continuously monitors pressure distribution, alerting users and caregivers in real-time to repositioning needs. This innovative solution enables early intervention, preventing pressure ulcers, and ensuring user comfort and affordability.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

Founded in 2019, Occuity specializes in the research, design, and manufacture of non-contacting optical instruments for use in healthcare diagnostics and monitoring. The company develops a range of handheld meters that work by shining light into the eye and analyzing the return signal, enabling direct measurements for optometrists, ophthalmologists, and other healthcare professionals to monitor various conditions including diabetes and Alzheimer's disease.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Lucida Medical develops artificial intelligence–based healthcare technology to aid clinicians in the detection and diagnosis of cancer. Its platform analyzes imaging data from MRI and integrates imaging and multi-omics biomarkers and reporting tools to support cancer screening and diagnosis, with the aim of making detection more accurate, accessible, and faster while reducing costs. The company’s first product, Pi, is designed to assist in diagnosing prostate cancer using multiparametric or diffusion MRI and is a CE marked medical device.

Bioliberty is a medtech startup developing rehabilitation solutions and robotic gloves enabled by artificial intelligence to aid muscle recovery for degenerative and traumatic conditions. The company focuses on assistive robotics and rehabilitative devices to help patients with stroke, motor neuron disease, multiple sclerosis, rheumatoid arthritis, and osteoarthritis improve hand strength for daily tasks and live independently at home.

TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.

ZiO Health is a biotechnology company that develops pocket-sized devices featuring proprietary biosensor technology and machine learning algorithms. These devices enable real-time laboratory testing at the point-of-care, enhancing patient care by combining immediate results with individual patient profiles.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

Boost Innovations is a company focused on developing products specifically for women, with a particular emphasis on breast prostheses. Its primary offering is a specialized breast form designed to enhance comfort and usability for individuals who have undergone surgery. The prosthesis is engineered to remain securely in place when worn with post-surgery underwear, and it is suitable for various activities, including swimming and exercising. By prioritizing breathability and functionality, Boost Innovations aims to boost the confidence of its users and cater to their unique needs.

BrightSign Technology Limited is a company based in London, United Kingdom, that specializes in developing wearable technology solutions aimed at assisting individuals with speech disabilities. Founded in 2017, BrightSign has created a data glove embedded with sensors designed to translate sign language and hand gestures into text and speech. This innovative glove features built-in hardware, including a small display screen for visual output and a speaker for audio output, eliminating the need for external smart devices. The company's technology leverages artificial intelligence and machine learning to enable effective communication for users, including children with speech disabilities and individuals affected by conditions such as strokes and autism. BrightSign's mission is to empower millions of individuals with non-verbal disabilities, allowing them to engage directly with the public without the need for an interpreter.

Orthonika Limited, established in London in 2014, specializes in the manufacture of MenisciKnit, an innovative anatomical meniscus replacement designed to address the high unmet need for effective treatment of meniscus injuries. Its unique fiber-reinforced structure aims to restore full joint biomechanics and reduce the risk of osteoarthritis.

Rescape Innovation Limited is a healthcare technology company based in Cardiff, United Kingdom, established in 2017. The company specializes in the design and manufacture of healthcare equipment, focusing on virtual reality distraction therapy. Rescape Innovation's technologies aim to address challenges in the healthcare sector, particularly in reducing anxiety and pain for patients while enhancing their overall experience. By leveraging virtual reality, the company seeks to improve communication and management of stress-related issues in clinical settings.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Calla Lily Clinical Care is a women's health company focused on developing innovative drug delivery systems. Their proprietary platform, Callavid®, enables intravaginal drug delivery for various indications, including fertility and pregnancy support, prevention of recurrent bacterial vaginosis, hormone replacement therapy for menopause, and biomarker-based diagnostic tests.

QV Bioelectronics develops an innovative electric field therapy implant, GRACE, designed to extend the lives of brain tumor patients while maintaining their quality of life. This first-of-its-kind device targets glioblastoma, a cancer with poor outcomes, by slowing tumor growth and sparing healthy tissue.

Spacebands develops innovative software and wearable technology focused on enhancing workplace safety. The company's flagship product is a wearable device that tracks social distancing and monitors decibel levels, alerting users through beeping and vibrating when they come too close to others wearing the device. This technology aims to provide an accessible and effective solution for social distancing and contact tracing, helping to create safer environments in various settings. By integrating real-time monitoring capabilities, Spacebands addresses the challenges of maintaining safety in shared spaces.

PatientMpower specializes in remote monitoring solutions for patients with chronic diseases, particularly those with respiratory conditions. The company develops applications that integrate with devices such as spirometers and pulse oximeters, allowing patients to conduct health measurements from home. These devices connect to a smartphone application, which facilitates the transmission of real-time data to healthcare providers. This integration enhances the ability of healthcare workers to deliver high-quality care and monitor patient progress effectively. Additionally, PatientMpower’s solutions contribute to research efforts aimed at improving treatment methodologies, ultimately supporting better health outcomes for patients.

Fallouh Healthcare specializes in the development and manufacturing of medical devices and AI-based software for cardiac surgery. Their products aim to enhance patient safety and streamline surgical workflows. Key offerings include systems for monitoring and protecting the heart during surgery, and AI-driven tools to detect and prevent complications like tamponade.

NIQS Technology is a spin-out from the University of Leeds specializing in innovative quantum glucose management solutions aimed at transforming diabetes care. The company has developed a patented, non-invasive glucose monitoring technology that employs a contact-based wearable device made of nano-engineered glass. This device mimics the optical properties of glucose, allowing for continuous, accurate glucose level monitoring without the need for needles or blood sampling. By providing accessible and user-friendly monitoring solutions, NIQS Technology seeks to empower individuals living with diabetes to manage their condition more effectively and improve their overall quality of life, while minimizing the risk of complications associated with traditional glucose management methods.

WeWALK is a London‑based company that develops a smart cane to enhance mobility for visually impaired individuals. The cane incorporates an ultrasonic sensor that detects obstacles above chest level and delivers haptic alerts, allowing users to navigate safely. It is paired with a mobile application that offers outdoor navigation, way‑finding, and integration with public transportation data. Additional features include voice control via Amazon Alexa and customizable settings. Founded in 2017, WeWALK applies artificial intelligence and user‑centric design to create a safer, more independent experience for people with visual impairments.

Emm is a company focused on consumer health technology, developing tools to help individuals manage their health on their terms. It is building a menstrual cup with integrated biosensors designed to track biometric data and deliver personalized insights about menstrual health. The device aims to redefine period experiences by providing actionable information that helps users understand their health through technology and expert knowledge.

Brainstem is a DePIN to collect and utilise wearable health data. Our mission is to revolutionize healthcare and improve lives through remote screening, ongoing monitoring, digital treatment alternatives, and tools to share data with practitioners, researchers, and others. We are committed to building a network of users who are willing to share their data and embracing collaboration with smart minds to speed innovation. With our vision of being a 24/7 virtual health assistant specializing in sleep, mental, cardio, and neuro health, we are at the forefront of digital health.

52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.

Silveray develops affordable large-area direct conversion detectors for the X-ray imaging market.

Acurable is a London-based MedTech company that develops wearable sensor-based devices for at‑home diagnosis and management of respiratory conditions. Its flagship AcuPebble captures internal body sounds using non-invasive sensors and transmits data to a mobile device, where algorithms extract clinical parameters and biomarkers relevant to sleep apnea. The system enables remote assessments by patients and healthcare providers, supporting home monitoring without hospital visits and facilitating more accessible, cost-effective care. Founded in 2016, Acurable emphasizes research-driven development to advance at‑home respiratory care.

ProtonDx is a diagnostic company delivering molecular testing through a point-of-care platform that enables rapid and sensitive detection of multiple infectious pathogens from patient samples. Its microchip-based technology combines molecular biology and machine learning and can be rapidly deployed in hospitals to assist clinicians in diagnosing infectious diseases, managing infected patients, and providing real-time insights for outbreak tracking.

Transdermal Diagnostics is a technology platform focused on the prevention, diagnosis, and management of chronic conditions, starting with diabetes. It offers a wearable system that provides needle-free, continuous glucose monitoring through affordable disposable patches, enabling people with diabetes and prediabetes to gain biological insights and make informed decisions for healthier living.

On The Mend develops a digital rehabilitation platform aimed at enhancing patient outcomes and experiences. Its platform captures key patient data, facilitates caseload management, tracks patient progress, and enables healthcare professionals to collaborate effectively.

OKKO Health offers a SaaS platform for remote eye health monitoring. It combines vision science, clinical insight, and game technology to predict deterioration and enable personalized care.

Ocuwell develops ophthalmic diagnostic technology, offering a cloud-based platform that combines a portable corneal topographer, digital imaging, and data-driven analysis to support eye health assessment. The company serves ophthalmologists, optometrists, and vision care providers through a B2B and software-as-a-service model, enabling accurate diagnostics and early detection of corneal conditions while making quality eye care more accessible and affordable. Built on 25 years of scientific research, Ocuwell aims to transform corneal diagnostics and improve patient access to advanced eye care worldwide.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Vamstar is a company that operates a B2B healthcare supply chain platform aimed at streamlining sourcing and procurement processes for medical device and pharmaceutical companies. The platform utilizes machine learning to capture demand for medical device and pharmaceutical products and services globally, matching this demand with suppliers worldwide. This enables customers to optimize their sourcing and procurement processes, reduce costs, and improve access to essential healthcare products and services. Vamstar's platform aggregates over $2 trillion of global demand across more than 70 countries, providing real-time analytics to facilitate transactions between buyers and suppliers. The company has onboarded some of the world's most innovative healthcare companies and continues to expand its capabilities in the digital marketplace.

SleepCogni is developing a sleep aid technology that delivers a wind-down process to promote sleep. The device provides cognitive-behavioral therapy through biofeedback delivered via visual, auditory, and tactile cues and is triggered manually. It monitors physiological and behavioral sleep-related measures, including heart rate, mental alertness, skin temperature, and movement using sensors on the index finger, to guide users toward sleep initiation and improve sleep quality, addressing insomnia.

MiiCare designs an AI-driven home care platform for aging individuals, co-created with older adults, families, and caregivers. It transforms homes into safe, connected spaces using telehealth devices, passive sensors, acoustic sensing, and AI digital therapeutics. The platform's conversational AI, Monica, acts as a health coach, monitoring users' homes, ensuring medication adherence, motivating healthy habits, and alerting caregivers to behavior or health changes. MiiCare aims to reduce care costs, staff burden, and hospitalizations while improving user engagement.

MiiCare designs an AI-driven home care platform for aging individuals, co-created with older adults, families, and caregivers. It transforms homes into safe, connected spaces using telehealth devices, passive sensors, acoustic sensing, and AI digital therapeutics. The platform's conversational AI, Monica, acts as a health coach, monitoring users' homes, ensuring medication adherence, motivating healthy habits, and alerting caregivers to behavior or health changes. MiiCare aims to reduce care costs, staff burden, and hospitalizations while improving user engagement.

Calla Lily Clinical Care is a women's health company focused on developing innovative drug delivery systems. Their proprietary platform, Callavid®, enables intravaginal drug delivery for various indications, including fertility and pregnancy support, prevention of recurrent bacterial vaginosis, hormone replacement therapy for menopause, and biomarker-based diagnostic tests.

Oxford Heartbeat develops medical device software to improve surgical planning and execution. The platform allows surgeons to visualize what is happening inside blood vessels and surrounding tissues and bones, offering unprecedented visibility for minimally invasive, keyhole procedures. Through predictive computations, big data and AI, it enables rehearsals of procedures and helps choose the best surgical scenario for each patient in advance. Better preparation aims to reduce complication rates and related costs while delivering improved patient care.

CryoLogyx is an early-stage biotechnology company that develops cryopreservation technology to produce frozen, ready-to-use cells for drug discovery, diagnostics, and cell therapies. Its approach protects cells during freezing using cryoprotectants, enabling viable cells to be stored and transported in formats tailored to researchers' needs. The technology aims to transform how cells are stored and delivered, ensuring cells and cell therapies are available in the desired format whenever needed.

Bea Fertility is a monthly subscription program that provides users with at-home fertility treatment and ovulation tracking. The kits offered by Bea Fertility include an intracervical insemination device, as well as pregnancy tests, fertility trackers, and sperm donation pots. Bea Fertility democratizes effective and affordable fertility treatment for individuals and couples who are having difficulty conceiving.

Founded in 2015 and based in Cambridge, UK, Camallergy is a biopharmaceutical company focused on developing innovative treatments for food allergies. Its lead product is an oral immunotherapy designed to provide significant protection against peanut allergy within just three months.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

Vamstar is a company that operates a B2B healthcare supply chain platform aimed at streamlining sourcing and procurement processes for medical device and pharmaceutical companies. The platform utilizes machine learning to capture demand for medical device and pharmaceutical products and services globally, matching this demand with suppliers worldwide. This enables customers to optimize their sourcing and procurement processes, reduce costs, and improve access to essential healthcare products and services. Vamstar's platform aggregates over $2 trillion of global demand across more than 70 countries, providing real-time analytics to facilitate transactions between buyers and suppliers. The company has onboarded some of the world's most innovative healthcare companies and continues to expand its capabilities in the digital marketplace.

Vamstar is a company that operates a B2B healthcare supply chain platform aimed at streamlining sourcing and procurement processes for medical device and pharmaceutical companies. The platform utilizes machine learning to capture demand for medical device and pharmaceutical products and services globally, matching this demand with suppliers worldwide. This enables customers to optimize their sourcing and procurement processes, reduce costs, and improve access to essential healthcare products and services. Vamstar's platform aggregates over $2 trillion of global demand across more than 70 countries, providing real-time analytics to facilitate transactions between buyers and suppliers. The company has onboarded some of the world's most innovative healthcare companies and continues to expand its capabilities in the digital marketplace.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Oxford Endovascular develops a neurovascular device to treat brain aneurysms. The device uses origami-inspired engineering with a laser-cut metal alloy that has shape-memory, enabling a catheter-delivered implant to expand into a tiny mesh tube that conforms to the vessel. By diverting blood flow away from the aneurysm, it promotes healing and reduces the risk of rupture.

Ingenion Medical is a medical device company focused on developing innovative solutions for patients suffering from chronic urinary retention and incontinence. The company aims to provide clinically relevant and cost-effective products that mimic natural urination, effectively addressing issues related to urinary flow and control. By eliminating the need for drainage bags, Ingenion Medical enhances the management of urinary conditions, improving the quality of life for its patients.

Callaly is a period care company that develops innovative feminine hygiene products. Its flagship product is the Tampliner, an organic, leak-proof tampon invented by gynecologists and manufactured to medical-grade standards in Britain. Sold initially through customizable online subscriptions, Callaly's products prioritize comfort, sustainability, and transparency.

OKKO Health offers a SaaS platform for remote eye health monitoring. It combines vision science, clinical insight, and game technology to predict deterioration and enable personalized care.

MiiCare designs an AI-driven home care platform for aging individuals, co-created with older adults, families, and caregivers. It transforms homes into safe, connected spaces using telehealth devices, passive sensors, acoustic sensing, and AI digital therapeutics. The platform's conversational AI, Monica, acts as a health coach, monitoring users' homes, ensuring medication adherence, motivating healthy habits, and alerting caregivers to behavior or health changes. MiiCare aims to reduce care costs, staff burden, and hospitalizations while improving user engagement.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

Ablatus Therapeutics Limited is a medical device company based in Norwich, United Kingdom, focused on developing and commercializing innovative tissue ablation technology for the treatment of challenging and often inoperable solid cancer tumors. Founded in 2015, the company has created a proprietary Bimodal Electric Tissue Ablation system that utilizes radiofrequency (RF) energy to generate localized heating and effectively destroy target tissues. This advanced approach provides clinicians with new options for treating tumors, aiming to improve patient outcomes in oncology care.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

OKKO Health offers a SaaS platform for remote eye health monitoring. It combines vision science, clinical insight, and game technology to predict deterioration and enable personalized care.

OKKO Health offers a SaaS platform for remote eye health monitoring. It combines vision science, clinical insight, and game technology to predict deterioration and enable personalized care.

QV Bioelectronics develops an innovative electric field therapy implant, GRACE, designed to extend the lives of brain tumor patients while maintaining their quality of life. This first-of-its-kind device targets glioblastoma, a cancer with poor outcomes, by slowing tumor growth and sparing healthy tissue.

Vitrue Health specializes in digital technology aimed at reducing musculoskeletal issues through accurate measurement and assessment. The company's flagship products, including VIDA and Vitrue EVVA, utilize advanced computer vision and biomechanics to objectively evaluate musculoskeletal health in various settings, from workplaces to clinical environments. VIDA specifically addresses the needs of desk workers by assessing their workspaces and ensuring compliance with ergonomic standards, helping to mitigate common problems like back and neck pain. Vitrue EVVA employs depth sensors for clinical-grade evaluations, which are valuable in orthopaedics, injury prevention in elite sports, and health screenings. By providing detailed reports and predictive insights regarding functional ability and core strength, Vitrue Health empowers both clinicians and patients to identify issues early, design optimal treatment plans, and engage patients in their recovery. The company’s mission is to establish a new foundation for musculoskeletal healthcare, aiming to alleviate pain and improve the quality of life for millions.

Arete Medical Technologies is a startup focused on developing medical devices and software aimed at precision management of chronic diseases, with an initial emphasis on asthma and chronic obstructive pulmonary disease (COPD). The company creates digital therapeutic devices that allow for personalized and preventative care in chronic respiratory conditions. Arete Medical utilizes advanced hardware and software technologies to reduce sensor costs and incorporates artificial intelligence and biomechanical modeling to enhance patient outcomes. This approach aims to support medical practitioners in improving patient care and increasing the efficiency of healthcare systems.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

Vamstar is a company that operates a B2B healthcare supply chain platform aimed at streamlining sourcing and procurement processes for medical device and pharmaceutical companies. The platform utilizes machine learning to capture demand for medical device and pharmaceutical products and services globally, matching this demand with suppliers worldwide. This enables customers to optimize their sourcing and procurement processes, reduce costs, and improve access to essential healthcare products and services. Vamstar's platform aggregates over $2 trillion of global demand across more than 70 countries, providing real-time analytics to facilitate transactions between buyers and suppliers. The company has onboarded some of the world's most innovative healthcare companies and continues to expand its capabilities in the digital marketplace.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Kheiron Medical Technologies is a London-based medical technology company that develops Mia, an AI-powered mammography screening tool designed to help radiologists detect breast cancer. The system combines deep learning with radiology insights to improve detection efficiency, consistency, and accuracy across imaging workflows. Incorporated in 2016 and formerly known as Maesterai, the company maintains an international presence with offices in London, San Francisco, Budapest, and Amsterdam, aiming to advance precision radiology and improve outcomes for cancer patients.

Arete Medical Technologies is a startup focused on developing medical devices and software aimed at precision management of chronic diseases, with an initial emphasis on asthma and chronic obstructive pulmonary disease (COPD). The company creates digital therapeutic devices that allow for personalized and preventative care in chronic respiratory conditions. Arete Medical utilizes advanced hardware and software technologies to reduce sensor costs and incorporates artificial intelligence and biomechanical modeling to enhance patient outcomes. This approach aims to support medical practitioners in improving patient care and increasing the efficiency of healthcare systems.

ExplantLab is a research organization based in Newcastle upon Tyne, United Kingdom. It focuses on investigating the connections between patients' genetics and the design, manufacturing, and performance of medical devices. The company aims to enhance the lives of patients by developing innovative medical solutions tailored to individual genetic profiles.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

OKKO Health offers a SaaS platform for remote eye health monitoring. It combines vision science, clinical insight, and game technology to predict deterioration and enable personalized care.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

Callaly is a period care company that develops innovative feminine hygiene products. Its flagship product is the Tampliner, an organic, leak-proof tampon invented by gynecologists and manufactured to medical-grade standards in Britain. Sold initially through customizable online subscriptions, Callaly's products prioritize comfort, sustainability, and transparency.

Echopoint Medical Ltd, established in 2018 and headquartered in London, specializes in developing medical devices that incorporate optical-fibre based sensors. The company leverages optical fibre sensing technologies to enhance precision and efficacy in invasive cardiology and other minimally invasive procedures, with a focus on transforming the diagnosis and treatment of cardiovascular diseases.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.

Vitrue Health specializes in digital technology aimed at reducing musculoskeletal issues through accurate measurement and assessment. The company's flagship products, including VIDA and Vitrue EVVA, utilize advanced computer vision and biomechanics to objectively evaluate musculoskeletal health in various settings, from workplaces to clinical environments. VIDA specifically addresses the needs of desk workers by assessing their workspaces and ensuring compliance with ergonomic standards, helping to mitigate common problems like back and neck pain. Vitrue EVVA employs depth sensors for clinical-grade evaluations, which are valuable in orthopaedics, injury prevention in elite sports, and health screenings. By providing detailed reports and predictive insights regarding functional ability and core strength, Vitrue Health empowers both clinicians and patients to identify issues early, design optimal treatment plans, and engage patients in their recovery. The company’s mission is to establish a new foundation for musculoskeletal healthcare, aiming to alleviate pain and improve the quality of life for millions.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

MediSieve Ltd. is a London-based medical device company specializing in Magnetic Blood Filtration (MBF) technology aimed at treating blood-borne diseases. Founded in 2014, the company has developed a system that utilizes a magnetic filter to physically remove infected blood cells from a patient's bloodstream. The process involves circulating blood through an external loop where targeted magnetic particles are infused, binding to disease-relevant targets. This filtered blood then passes through a magnetic filter that captures the particles and bound targets, allowing the unaffected blood to return to the patient without the particles entering their body. MediSieve's innovative approach is applicable to various conditions, including malaria, leukaemia, sepsis, and other blood-borne diseases, enhancing the efficacy and safety of existing therapies. The company operates out of the Imperial Incubator in White City, London, where it conducts product development and validation in its dedicated laboratory facilities.

Founded in 2015, SageTech Medical develops innovative anesthetic technology for human and veterinary healthcare providers. Its patented process captures, extracts, and purifies inhalational anaesthetic agents, reducing costs and environmental pollution. The company offers solutions ranging from industrial-scale bulk capture to integrated recycling systems within anaesthetic machines.

BIOS Health is a pioneering company focused on developing neural digital therapies by harnessing data-driven insights from the human nervous system. Co-founded by researchers from Cambridge University, the firm aims to revolutionize precision medicine through the identification of neural biomarkers that link nerve activity to various medical conditions. BIOS's innovative approach holds promise for treating chronic diseases such as hypertension, diabetes, rheumatoid arthritis, and neurodegenerative disorders like Parkinson's and Alzheimer's. The company's expertise encompasses a diverse range of fields, including neuroscience, machine learning, software engineering, and biotechnology, allowing it to create advanced solutions for improving the quality of life for individuals suffering from these conditions. Additionally, BIOS is engaged in developing prosthetic connectors that standardize the interface between bionic devices and the body's nervous and soft-tissue systems, enabling enhanced control and feedback for patients with prosthetics.

Callaly is a period care company that develops innovative feminine hygiene products. Its flagship product is the Tampliner, an organic, leak-proof tampon invented by gynecologists and manufactured to medical-grade standards in Britain. Sold initially through customizable online subscriptions, Callaly's products prioritize comfort, sustainability, and transparency.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Almac Group is a global contract development and manufacturing organization that provides a comprehensive suite of services to pharmaceutical and biotechnology companies. Its offerings span research and development, biomarker discovery, active pharmaceutical ingredient production, formulation development, clinical trial supply, interactive voice response system technology, commercial‑scale manufacturing, and companion diagnostic development. Founded more than four decades ago, the privately held company employs over 4,500 professionals and is headquartered in Craigavon, Northern Ireland. Almac operates facilities across the United Kingdom, Ireland, the United States (Pennsylvania, North Carolina, California), and Asia (Singapore, Tokyo), and continually invests in advanced capabilities such as biocatalytic API synthesis, clinical trial data management, and the clinical supply chain. The organization also encompasses specialized units, including Almac Sciences, which offers analytical testing for drug substances and products, and Almac Discovery, a research‑driven oncology company focused on early‑stage drug discovery.

Cadscan Limited is a company specializing in the development of 3-dimensional (3D) products for the healthcare, dental, and industrial sectors. Founded in 2011 and based in Chester, United Kingdom, Cadscan integrates imaging, 3D printing, and 3D visualization technologies to create innovative products. Its offerings include 3D printed insoles, solutions for wound management, and robotic inspection systems. The company also develops a range of medical devices, such as custom orthotics, and employs advanced 3D scanning techniques for various applications. Cadscan Limited's focus on combining cutting-edge technology with practical healthcare solutions positions it as a key player in its industry.

Bioinduction is a company focused on developing innovative neuromodulation devices aimed at treating chronic pain and various neurological disorders. Their flagship product is a skull-mounted deep brain stimulation (DBS) platform, which integrates advanced features such as neural recording and target steering. This design enhances the productivity of surgical teams while prioritizing patient comfort, as the unique placement on the skull offers significant advantages over traditional DBS devices. Bioinduction's approach represents a faster and simpler solution in the field of deep brain stimulation, positioning the company as a notable player in neurological treatment technology.